Candel Therapeutics, Inc. CADL Proceeds from issuances of debt

Proceeds from issuances of debt at other companies

TeraWulfWULF

$92.75M—

Guidewire SoftwareGWRE

$0—

Donaldson CompanyDCI

$40M-27.3%

Micron TechnologyMU

$1.75B—

IngredionINGR

$158M+49.1%

FAN

Diamondback EnergyFANG

$2.53B-27.4%

Other financials

Income statement

See full

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

See full

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

See full

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

See full

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

See full

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

See full

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.

The official record: Candel Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s proceeds from issuances of debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s proceeds from issuances of debt?: Candel Therapeutics, Inc. (CADL) reported proceeds from issuances of debt of $11.99M in Q4 2025.